Eli Lilly Q2 2026 earnings call centered on the company's next obesity franchise, with executives outlining plans to file retatrutide in Q1 2027 while defending a contested regulatory pathway that could determine whether the triple agonist receives 12 years of biologic exclusivity. Executives also disclosed new clinical data for pirtobrutinib in chronic lymphocytic leukemia (CLL) that management said represented the first Phase III regimen to outperform a venetoclax-containing control arm.
Revenue grew 48% year-on-year to USD 23.0 billion in Q2, driven by tirzepatide (Zepbound, Mounjaro); Lilly raised full-year 2026 revenue guidance to USD 85 billion–USD 87 billion. Management highlighted accelerating momentum for the oral drug orforglipron (Foundayo), with President of Lilly USA Ilya Yuffa disclosing that the US prescriber base has expanded from approximately 8,000 to 36,000 physicians since the previous earnings call. Weekly prescription volumes nearly doubled during July following CVS formulary access, direct-to-consumer advertising, and the July 1 launch of the Medicare GLP-1 Bridge program. Lilly also reported encouraging early launches outside the US, with management arguing that oral GLP-1 therapy is expanding the treated obesity population rather than cannibalizing injectable incretins, as most new patients are GLP-1 naïve.
Key Strategic Signals
Retatrutide BLA classification under active litigation — US submission targeted Q1 2027: Chief Executive David Ricks confirmed that Lilly continues to pursue a biologics license application (BLA) for retatrutide, despite an ongoing legal dispute with the US FDA over the appropriate regulatory pathway. Ricks disclosed that an initial court ruling was "mixed" and that litigation remains active, while saying the company expects to submit the completed Phase III package in Q1 2027 once additional chemistry, manufacturing, and controls (CMC) work is finalized.
The BLA classification has broader significance in relation to the general development of peptides in general. Ricks noted that a biologic designation would provide 12 years of data exclusivity versus the 5 years available under a new drug application (NDA). The TRIUMPH program — three completed Phase III trials in obesity, type 2 diabetes, and cardiovascular disease — generated weight loss approaching bariatric surgery levels at higher doses, management said, with Kenneth Custer citing a 75% reduction in osteoarthritis knee pain as illustrative of the molecule's potential indication breadth. Additional ongoing studies include metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis (MASH/NASH) and chronic lower back pain, with the latter expected to read out in 2027.
Pirtobrutinib BRUIN CLL-322 data filed globally after first venetoclax control arm defeat: Daniel Skovronsky confirmed that BRUIN CLL-322 Phase III data have been submitted to global regulatory authorities. Adding Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, to a fixed-duration venetoclax and rituximab regimen reduced the risk of disease progression or death by 45% in the overall previously treated CLL population; in patients who had received one prior covalent BTK inhibitor, the reduction was 68%. Skovronsky described these as the first Phase III results to outperform a venetoclax-containing control arm in CLL, and said the company believes the data have the potential to establish a new standard of care. The competitive context is significant: venetoclax-based fixed-duration regimens are currently a dominant treatment approach in relapsed CLL, and approval of the triple combination would position Jaypirca as an additive rather than alternative therapy.